NMRA

SEC source: 0001610717-24-000475 · form4.xml · derivative · entry 6

Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 136,210

Underlying: Common Stock · 136,210 shares

Expires 2033-01-18

F2 · kind: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

F2 · derivative.exercise_date: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

F1 · ownership.nature: Shares held by Aurora Family Trust.

SEC source: 0001610717-24-000475 · form4.xml · derivative · entry 5

Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,901

Underlying: Common Stock · 136,210 shares

Expires 2033-01-18

F2 · kind: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

F2 · derivative.exercise_date: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

F4 · balance_after: 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000475 · form4.xml · derivative · entry 4

Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 137,538

Underlying: Common Stock · 137,538 shares

Expires 2031-09-20

F2 · kind: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

F2 · derivative.exercise_date: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

F1 · ownership.nature: Shares held by Aurora Family Trust.

SEC source: 0001610717-24-000475 · form4.xml · derivative · entry 3

Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,890

Underlying: Common Stock · 137,538 shares

Expires 2031-09-20

F2 · kind: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

F2 · derivative.exercise_date: Represents fully vested stock options transferred pursuant to an option transfer agreement dated September 12, 2024 between the Reporting Person and Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

F3 · balance_after: 25% of the shares subject to the option vest on the first anniversary measured from August 2, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000478 · form4.xml · nonDerivative · entry 1

Lenz Robert A. · CIK 0001992908 · Head of R&D

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 369,993

F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on June 12, 2024 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

F2 · price: This transaction was executed in multiple trades in prices ranging from $11.22 to $11.6050, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001610717-24-000457 · form4.xml · nonDerivative · entry 1

Pinto Joshua · CIK 0001992595 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 138,965

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 18, 2024 and subsequently amended on May 22, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $11.1572 to $11.58, inclusive. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · ownership.nature: Shares held by Maple DE Holdings LLC.

SEC source: 0001610717-24-000456 · form4.xml · nonDerivative · entry 3

Pinto Joshua · CIK 0001992595 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 154,658

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 18, 2024 and subsequently amended on May 22, 2024.

F5 · price: This transaction was executed in multiple trades at prices ranging from $11.61 to $11.98, inclusive. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · ownership.nature: Shares held by Maple DE Holdings LLC.

SEC source: 0001610717-24-000456 · form4.xml · nonDerivative · entry 2

Pinto Joshua · CIK 0001992595 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 186,300

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 18, 2024 and subsequently amended on May 22, 2024.

F4 · price: This transaction was executed in multiple trades at prices ranging from $11.40 to $11.74, inclusive. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · ownership.nature: Shares held by Maple DE Holdings LLC.

SEC source: 0001610717-24-000456 · form4.xml · nonDerivative · entry 1

Pinto Joshua · CIK 0001992595 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See footnote

Disclosed balance after: 210,469

F1 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on April 18, 2024 and subsequently amended on May 22, 2024.

F2 · price: This transaction was executed in multiple trades at prices ranging from $11.43 to $12.06, inclusive. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · ownership.nature: Shares held by Maple DE Holdings LLC.

SEC source: 0001610717-24-000338 · form4.xml · derivative · entry 2

Ho Maykin · CIK 0001646395 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,571

Underlying: Common Stock · 28,571 shares

Expires 2034-06-12

F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.

SEC source: 0001610717-24-000338 · form4.xml · nonDerivative · entry 1

Ho Maykin · CIK 0001646395 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,100

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.

SEC source: 0001610717-24-000337 · form4.xml · derivative · entry 2

Piacquad David · CIK 0001602343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,571

Underlying: Common Stock · 28,571 shares

Expires 2034-06-12

F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.

SEC source: 0001610717-24-000337 · form4.xml · nonDerivative · entry 1

Piacquad David · CIK 0001602343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,100

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.

SEC source: 0001610717-24-000336 · form4.xml · derivative · entry 2

Halawa Alaa · CIK 0001992622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,571

Underlying: Common Stock · 28,571 shares

Expires 2034-06-12

F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.

SEC source: 0001610717-24-000336 · form4.xml · nonDerivative · entry 1

Halawa Alaa · CIK 0001992622 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,100

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.

SEC source: 0001610717-24-000335 · form4.xml · derivative · entry 2

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,571

Underlying: Common Stock · 28,571 shares

Expires 2034-06-12

F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.

SEC source: 0001610717-24-000335 · form4.xml · nonDerivative · entry 1

Fust Matthew K · CIK 0001397266 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,100

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.

SEC source: 0001610717-24-000334 · form4.xml · derivative · entry 7

Burow Kristina · CIK 0001569248 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,571

Underlying: Common Stock · 28,571 shares

Expires 2034-06-12

F9 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.

SEC source: 0001610717-24-000334 · form4.xml · nonDerivative · entry 1

Burow Kristina · CIK 0001569248 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,717

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024.

SEC source: 0001610717-24-000222 · form4.xml · nonDerivative · entry 1

Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,500

F1 · kind: On April 22, 2024, the Reporting Person transferred, for no consideration, 114,703 shares of Common Stock to Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.

SEC source: 0001610717-24-000380 · form4.xml · nonDerivative · entry 1

Pinto Joshua · CIK 0001992595 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 238,965

F1 · kind: On April 8, 2024, the Reporting Person transferred 238,965 shares of Common Stock to a family limited liability company (the "Family LLC") in a transaction exempt from reporting pursuant to Rule 16a-13. The transaction reported herein reflects the transfer for no consideration of membership interests in the Family LLC to a trust of which the Reporting Person is a beneficiary for estate planning purposes. The Reporting Person continues to exercise investment control over the Common Stock held by the Family LLC.

F2 · ownership.nature: Shares held by Maple DE Holdings LLC, which is the entity defined above as "Family LLC".

SEC source: 0001610717-24-000067 · form4.xml · derivative · entry 2

Suh Carol Y. · CIK 0001992789 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2034-02-13

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000067 · form4.xml · nonDerivative · entry 1

Suh Carol Y. · CIK 0001992789 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,674

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000063 · form4.xml · derivative · entry 2

Lenz Robert A. · CIK 0001992908 · Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-02-13

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000063 · form4.xml · nonDerivative · entry 1

Lenz Robert A. · CIK 0001992908 · Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 402,941

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000069 · form4.xml · derivative · entry 2

Pinto Joshua · CIK 0001992595 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2034-02-13

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000069 · form4.xml · nonDerivative · entry 1

Pinto Joshua · CIK 0001992595 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 323,965

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000068 · form4.xml · derivative · entry 2

Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 195,000 shares

Expires 2034-02-13

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000068 · form4.xml · nonDerivative · entry 1

Aurora Daljit Singh · CIK 0001793971 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 212,203

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000066 · form4.xml · derivative · entry 2

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,500

Underlying: Common Stock · 342,500 shares

Expires 2034-02-13

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000066 · form4.xml · nonDerivative · entry 1

BERNS PAUL L · CIK 0001202769 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,818,166

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000065 · form4.xml · derivative · entry 4

Gosebruch Henry O · CIK 0001659625 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2034-02-13

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000065 · form4.xml · nonDerivative · entry 1

Gosebruch Henry O · CIK 0001659625 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 462,345

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000064 · form4.xml · derivative · entry 2

Milligan Michael Lee · CIK 0001993953 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,250

Underlying: Common Stock · 41,250 shares

Expires 2034-02-13

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-24-000064 · form4.xml · nonDerivative · entry 1

Milligan Michael Lee · CIK 0001993953 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,448

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually measured from February 14, 2024 (the "Vesting Commencement Date"), such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001610717-23-000398 · form4.xml · derivative · entry 1

Duncan Jason · CIK 0001741553 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2033-12-10

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001062993-23-022481 · form4.xml · nonDerivative · entry 2

ARCH Venture Partners XII, LLC · CIK 0001979548 · 10% owner

ARCH Venture Partners XII, L.P. · CIK 0001979765 · 10% owner

ARCH Venture Fund XII, L.P. · CIK 0001906837 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund VIII Overage, L.P.

Disclosed balance after: 2,321,566

F1 · kind: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones. Shares were received without any action by Reporting Persons. No additional consideration was paid for the shares.

F2 · price: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

F3 · ownership.nature: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001062993-23-022481 · form4.xml · nonDerivative · entry 1

ARCH Venture Partners XII, LLC · CIK 0001979548 · 10% owner

ARCH Venture Partners XII, L.P. · CIK 0001979765 · 10% owner

ARCH Venture Fund XII, L.P. · CIK 0001906837 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

BYBEE CLINTON · CIK 0001219043 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund VII, L.P.

Disclosed balance after: 1,387,228

F1 · kind: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones. Shares were received without any action by Reporting Persons. No additional consideration was paid for the shares.

F1 · price: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones. Shares were received without any action by Reporting Persons. No additional consideration was paid for the shares.

F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001062993-23-022480 · form4.xml · nonDerivative · entry 2

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner

ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner

ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner

ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner

ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund VIII Overage, L.P.

Disclosed balance after: 2,321,566

F1 · kind: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones. Shares were received without any action by Reporting Persons. No additional consideration was paid for the shares.

F2 · price: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

F3 · ownership.nature: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001062993-23-022480 · form4.xml · nonDerivative · entry 1

ARCH Venture Partners X, LLC · CIK 0001769012 · 10% owner

ARCH Venture Fund X, L.P. · CIK 0001757011 · 10% owner

ARCH Venture Partners X, L.P. · CIK 0001782583 · 10% owner

ARCH Venture Fund X Overage, L.P. · CIK 0001757017 · 10% owner

ARCH Venture Partners X Overage, L.P. · CIK 0001768905 · 10% owner

ARCH Venture Partners VII, LLC · CIK 0001544443 · 10% owner

ARCH Venture Partners VII, L.P. · CIK 0001544444 · 10% owner

ARCH Venture Fund VII, L.P. · CIK 0001402439 · 10% owner

ARCH Venture Partners VIII, LLC · CIK 0001616165 · 10% owner

ARCH Venture Fund VIII Overage, L.P. · CIK 0001617237 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund VII, L.P.

Disclosed balance after: 1,387,228

F1 · kind: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones. Shares were received without any action by Reporting Persons. No additional consideration was paid for the shares.

F1 · price: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of certain contractual milestones. Shares were received without any action by Reporting Persons. No additional consideration was paid for the shares.

F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001062993-23-022479 · form4.xml · nonDerivative · entry 6

Burow Kristina · CIK 0001569248 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,617

F1 · kind: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones. Shares were received without any action by the Reporting Person. No additional consideration was paid for the shares.

F1 · price: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones. Shares were received without any action by the Reporting Person. No additional consideration was paid for the shares.

SEC source: 0001062993-23-022479 · form4.xml · nonDerivative · entry 2

Burow Kristina · CIK 0001569248 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund VIII Overage, L.P.

Disclosed balance after: 4,131,207

F1 · kind: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones. Shares were received without any action by the Reporting Person. No additional consideration was paid for the shares.

F1 · price: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones. Shares were received without any action by the Reporting Person. No additional consideration was paid for the shares.

F3 · ownership.nature: Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001062993-23-022479 · form4.xml · nonDerivative · entry 1

Burow Kristina · CIK 0001569248 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund VII, L.P.

Disclosed balance after: 1,387,228

F1 · kind: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones. Shares were received without any action by the Reporting Person. No additional consideration was paid for the shares.

F1 · price: Represents shares received as contingent consideration as a result of the completion of a contractual milestone being achieved by the Issuer. Issuer acquired Blackthorn Therapeutics, Inc. and agreed to pay in cash or in stock, at Issuer's discretion, to former stockholders of BlackThorn Therapeutics upon satisfaction of contractual milestones. Shares were received without any action by the Reporting Person. No additional consideration was paid for the shares.

F2 · ownership.nature: Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

SEC source: 0001062993-23-020933 · form4.xml · nonDerivative · entry 2

ARCH Venture Partners XII, LLC · CIK 0001979548 · 10% owner

ARCH Venture Partners XII, L.P. · CIK 0001979765 · 10% owner

ARCH Venture Fund XII, L.P. · CIK 0001906837 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XII, L.P.

Disclosed balance after: 4,131,207

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.89 to $12.00, inclusive.

F3 · ownership.nature: Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

F4 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023.

SEC source: 0001062993-23-020934 · form4.xml · nonDerivative · entry 2

Burow Kristina · CIK 0001569248 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XII, L.P.

Disclosed balance after: 4,131,207

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.89 to $12.00, inclusive.

F3 · ownership.nature: Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

F4 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023.

SEC source: 0001062993-23-020933 · form4.xml · nonDerivative · entry 1

ARCH Venture Partners XII, LLC · CIK 0001979548 · 10% owner

ARCH Venture Partners XII, L.P. · CIK 0001979765 · 10% owner

ARCH Venture Fund XII, L.P. · CIK 0001906837 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XII, L.P.

Disclosed balance after: 4,127,850

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.52 to $12.00, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

F3 · ownership.nature: Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

F4 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023.

SEC source: 0001062993-23-020934 · form4.xml · nonDerivative · entry 1

Burow Kristina · CIK 0001569248 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XII, L.P.

Disclosed balance after: 4,127,850

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.52 to $12.00, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.

F3 · ownership.nature: Beneficial ownership consists of 4,131,207 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

F4 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023.

SEC source: 0001062993-23-020714 · form4.xml · nonDerivative · entry 5

Burow Kristina · CIK 0001569248 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XII, L.P.

Disclosed balance after: 4,096,197

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.63 to $11.8922, inclusive.

F6 · ownership.nature: Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

F7 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023.

SEC source: 0001062993-23-020714 · form4.xml · nonDerivative · entry 4

Burow Kristina · CIK 0001569248 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XII, L.P.

Disclosed balance after: 4,090,766

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.62 to $11.61, inclusive.

F6 · ownership.nature: Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Kristina Burow is a member of the investment committee of AVP XII LLC (the AVP XII LLC Committee Member). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and the AVP XII LLC Committee Member may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Member disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

F7 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the reporting person continues to have a direct pecuniary interest and indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting person with respect to the issuer on September 20, 2023.

SEC source: 0001062993-23-020712 · form4.xml · nonDerivative · entry 5

ARCH Venture Partners XII, LLC · CIK 0001979548 · 10% owner

ARCH Venture Partners XII, L.P. · CIK 0001979765 · 10% owner

ARCH Venture Fund XII, L.P. · CIK 0001906837 · 10% owner

CRANDELL KEITH · CIK 0001219039 · 10% owner

GILLIS STEVEN · CIK 0001229592 · 10% owner

NELSEN ROBERT · CIK 0001219042 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By ARCH Venture Fund XII, L.P.

Disclosed balance after: 4,096,197

F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.63 to $11.8922, inclusive.

F6 · ownership.nature: Beneficial ownership consists of 4,096,197 shares of common stock held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

F7 · ownership.nature: As of the date hereof, in addition to securities owned by AVF XII, the investment committee members continue to have an indirect pecuniary interest in securities of the issuer as reported on a Form 4 filed by the reporting persons with respect to the issuer on September 20, 2023.